BMS' top drug faces patent challenge

Share this article:
The FDA approved a Canadian company’s application to produce a generic version of Bristol-Myers Squibb’s best-selling drug Plavix. The approval means generic maker Apotex could bring a generic form of the heart medication to market before a key Plavix patent expires in 2011. However, BMS and Sanofi-Aventis have sued Apotex over the validity and enforceability of the patent. A federal trial is scheduled for April. BMS “continues to believe that the patent is valid and that it is infringed, and with its alliance partner and patent-holder Sanofi-Aventis, is vigorously pursuing these cases,” BMS said in a statement. If the patent is held invalid, Apotex -- the first generic to file with the FDA -- stands to gain 180 days of generic market exclusivity on clopidogrel bisulfate. Plavix had 2005 US net sales of $3.2 billion.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.